Rakovina Therapeutics Inc. Announces 2023 Financial Results and Provides Corporate Update
April 26, 2024 20:38 ET
|
Rakovina Therapeutics Inc
VANCOUVER, British Columbia, April 26, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company”) a biopharmaceutical company committed to advancing new cancer therapies based...
Rakovina Therapeutics Presented at American Association of Cancer Research Annual Meeting at the San Diego Convention Center Today
April 09, 2024 16:05 ET
|
Rakovina Therapeutics Inc
VANCOUVER, British Columbia, April 09, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV), (“Rakovina” or the “Company”), a biopharmaceutical company dedicated to improving the lives...
Rakovina Therapeutics To Host Informational Webinar on April 3, 2024
April 01, 2024 07:15 ET
|
Rakovina Therapeutics Inc
VANCOUVER, British Columbia, April 01, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV), (“Rakovina Therapeutics” or the “Company”), a biopharmaceutical company dedicated to...
Rakovina Therapeutics Announces Strategic Pivot to AI
March 27, 2024 16:05 ET
|
Rakovina Therapeutics Inc
Rakovina Therapeutics announces Artificial Intelligence (AI) collaboration
Rakovina Therapeutics Inc. Announces Q3 2023 Financial Results and Provides Corporate Update
November 27, 2023 19:43 ET
|
Rakovina Therapeutics Inc
VANCOUVER, British Columbia, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company”), a biopharmaceutical company dedicated to improving the lives of cancer patients...
Rakovina Therapeutics Welcomes Prof. Artem Cherkasov to the Company’s Scientific Advisory Board
November 27, 2023 09:00 ET
|
Rakovina Therapeutics Inc
VANCOUVER, British Columbia, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (“the Company”), a biopharmaceutical company focused on the development of novel DNA-damage...
Rakovina Therapeutics Announces Appointment of New Scientific Advisory Board Member
November 20, 2023 09:13 ET
|
Rakovina Therapeutics Inc
VANCOUVER, British Columbia, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (“the Company”), a biopharmaceutical company focused on the development of novel DNA-damage...
Rakovina Therapeutics Inc. Announces Q2 2023 Financial Results and Provides Corporate Update
August 29, 2023 08:00 ET
|
Rakovina Therapeutics Inc
VANCOUVER, British Columbia, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company”), a biopharmaceutical company dedicated to improving the lives of cancer patients...
Rakovina Therapeutics Announces Results from 2023 Annual General Meeting
June 28, 2023 22:55 ET
|
Rakovina Therapeutics Inc
VANCOUVER, British Columbia, June 28, 2023 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSXV: RKV) (the “Company”), a biopharmaceutical company committed to advancing new cancer therapies based...
Rakovina Therapeutics Inc. Announces Q1 2023 Financial Results and Provides Corporate Update
May 31, 2023 09:05 ET
|
Rakovina Therapeutics Inc
VANCOUVER, British Columbia, May 31, 2023 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company”), a biopharmaceutical company dedicated to improving the lives of cancer patients...